Platinum Investment Management Ltd. reduced its position in Qiagen N.V. (NASDAQ:QGEN) by 2.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,108,060 shares of the company’s stock after selling 24,451 shares during the quarter. Qiagen comprises about 0.9% of Platinum Investment Management Ltd.’s portfolio, making the stock its 25th largest position. Platinum Investment Management Ltd. owned about 0.49% of Qiagen worth $34,903,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Oppenheimer Asset Management Inc. increased its holdings in Qiagen by 0.5% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock valued at $133,000 after buying an additional 20 shares during the period. M&T Bank Corp increased its holdings in Qiagen by 2.7% in the 2nd quarter. M&T Bank Corp now owns 8,155 shares of the company’s stock valued at $273,000 after buying an additional 215 shares during the period. Quadrant Capital Group LLC increased its holdings in Qiagen by 4.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after buying an additional 225 shares during the period. QS Investors LLC increased its holdings in Qiagen by 1.7% in the 2nd quarter. QS Investors LLC now owns 13,594 shares of the company’s stock valued at $456,000 after buying an additional 226 shares during the period. Finally, Public Employees Retirement Association of Colorado increased its holdings in Qiagen by 3.5% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 7,214 shares of the company’s stock valued at $242,000 after buying an additional 246 shares during the period. 62.37% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Qiagen N.V. (NASDAQ:QGEN) opened at $31.02 on Wednesday. Qiagen N.V. has a 1-year low of $27.51 and a 1-year high of $36.34. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68. The stock has a market cap of $7,112.11, a P/E ratio of 25.40, a P/E/G ratio of 1.91 and a beta of 1.10.
Qiagen (NASDAQ:QGEN) last posted its earnings results on Monday, November 6th. The company reported $0.32 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.32. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. The firm had revenue of $364.00 million for the quarter, compared to analyst estimates of $363.42 million. During the same period in the previous year, the firm posted $0.29 EPS. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. research analysts anticipate that Qiagen N.V. will post 1.25 earnings per share for the current fiscal year.
Several brokerages recently issued reports on QGEN. Cowen reaffirmed a “hold” rating and set a $33.00 price target on shares of Qiagen in a report on Thursday, September 28th. Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a report on Thursday, August 17th. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a report on Friday, December 1st. DZ Bank reaffirmed a “neutral” rating on shares of Qiagen in a report on Monday, August 28th. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Qiagen in a report on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $34.06.
TRADEMARK VIOLATION WARNING: This piece of content was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/12/06/qiagen-n-v-qgen-holdings-reduced-by-platinum-investment-management-ltd.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NASDAQ:QGEN).
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.